These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 25854646)

  • 1. Marine natural products as breast cancer resistance protein inhibitors.
    Cherigo L; Lopez D; Martinez-Luis S
    Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marine Natural Products as Models to Circumvent Multidrug Resistance.
    Long S; Sousa E; Kijjoa A; Pinto MM
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.
    Marighetti F; Steggemann K; Hanl M; Wiese M
    ChemMedChem; 2013 Jan; 8(1):125-35. PubMed ID: 23150210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
    Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
    Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
    Choi YH; Yu AM
    Curr Pharm Des; 2014; 20(5):793-807. PubMed ID: 23688078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.